Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06262789 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RAT-HEMATO : Return to Work After Malignant Hemopathy

Study acronym: RAT-HEMATO
StatusRecruiting
PhaseNot applicable
Started2024-09-27
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later across 2 updates Apr 1, 2027 → Mar 2028
See other at-risk trials from University Hospital, Angers

Amendment history

2026-09-01
notable
Study Status, Contacts/Locations v2
Primary completion pushed: 2027-09 → 2028-03
Completion pushed: 2027-09 → 2028-03
Study sites9→10
2026-08-06
notable
Study Status, Contacts/Locations v1
Recruitment opened
Primary completion pushed: 2027-04-01 → 2027-09
Completion pushed: 2027-04-01 → 2027-09
Start dateestimated 2024-03-15→confirmed 2024-09-27
Study sites7→9
2024-02-13
minor
Original filing
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.
Trial Details
NCT Number NCT06262789
Lead Sponsor University Hospital, Angers
Conditions Leukemia, Lymphoma, Multiple Myeloma
Enrollment 264 participants
Start Date 2024-09-27
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-04